Matthew Shawn Morris Sells 11,059 Shares of Privia Health Group, Inc. (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 11,059 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total value of $203,706.78. Following the transaction, the director now directly owns 70,101 shares in the company, valued at approximately $1,291,260.42. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Privia Health Group Price Performance

Shares of Privia Health Group stock traded up $0.38 during midday trading on Thursday, hitting $18.41. 782,205 shares of the company were exchanged, compared to its average volume of 940,409. The firm has a market cap of $2.18 billion, a P/E ratio of 96.90, a PEG ratio of 2.51 and a beta of 0.81. Privia Health Group, Inc. has a 52 week low of $17.54 and a 52 week high of $30.15. The firm has a 50 day simple moving average of $19.67 and a 200-day simple moving average of $21.16.

Privia Health Group (NASDAQ:PRVA) last announced its earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The business had revenue of $440.80 million for the quarter, compared to the consensus estimate of $425.81 million. During the same quarter in the previous year, the company posted $0.14 EPS. Privia Health Group’s revenue for the quarter was up 21.0% on a year-over-year basis. Equities research analysts expect that Privia Health Group, Inc. will post 0.26 earnings per share for the current year.

Institutional Investors Weigh In On Privia Health Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisors Preferred LLC acquired a new position in shares of Privia Health Group during the fourth quarter worth approximately $2,137,000. Loomis Sayles & Co. L P lifted its position in shares of Privia Health Group by 1.2% during the third quarter. Loomis Sayles & Co. L P now owns 623,870 shares of the company’s stock worth $14,349,000 after purchasing an additional 7,577 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Privia Health Group during the third quarter worth approximately $1,394,000. Riverbridge Partners LLC lifted its position in shares of Privia Health Group by 8.7% during the fourth quarter. Riverbridge Partners LLC now owns 4,342,385 shares of the company’s stock worth $100,005,000 after purchasing an additional 348,852 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Privia Health Group by 0.5% during the third quarter. Vanguard Group Inc. now owns 11,003,989 shares of the company’s stock worth $253,092,000 after purchasing an additional 51,317 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Wall Street Analysts Forecast Growth

PRVA has been the topic of a number of analyst reports. Barclays initiated coverage on Privia Health Group in a report on Wednesday, March 6th. They set an “equal weight” rating and a $22.00 price objective on the stock. Canaccord Genuity Group lowered their target price on Privia Health Group from $41.00 to $37.00 and set a “buy” rating on the stock in a report on Tuesday, March 19th. Bank of America lowered Privia Health Group from a “buy” rating to a “neutral” rating and lowered their target price for the company from $27.00 to $21.00 in a report on Thursday, February 22nd. Jefferies Financial Group started coverage on Privia Health Group in a report on Monday, February 26th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, TD Cowen lowered their target price on Privia Health Group from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $27.62.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.